ALCAM and neoplasm: Our tracking of MSC marker expression revealed progressive CD34 upregulation alongside declining ALCAM, CD44, and ICAM1 levels (16) (Figure 2K), indicating complex transcriptional reprogramming during MSC-to-tumor cell transitions.